ArticlePloS one2022
Antimicrobial resistance in shigellosis: A surveillance study among urban and rural children over 20 years in Bangladesh.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.Clinical and translational science · 2026Trial
- Pharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh.Scientific reports · 2024Trial
- Azithromycin for Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics.The Journal of infectious diseases · 2024Trial
- Review
- Gender and equity within antimicrobial resistance: a scoping review of evidence and policy in Bangladesh and Sri Lanka.BMC public health · 2026Article
- "Molecular Characterization of Extended Spectrum Beta-Lactamase Resistance in Pediatric Shigella Isolates in Egypt".Biochemical genetics · 2025Article
- Epidemiology of Shigella species and serotypes in children: a retrospective substudy of the MAL-ED observational birth cohort study.The Lancet. Microbe · 2025Observational
- Article
- Azithromycin treatment response as a probe to attribute bacterial etiologies of diarrhea using molecular diagnostics: a reanalysis of the Antibiotics for Children with Severe Diarrhea (ABCD) trial.Frontiers in microbiology · 2025Article
- Antibiotic resistance of enteropathogenic bacteria in a teaching hospital in North Khuzestan during a three-year period.Journal of family medicine and primary care · 2024Article
- Multidrug-resistant conjugative plasmid carrying mphA confers increased antimicrobial resistance in Shigella.Scientific reports · 2024Article
- Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024Article
- Article
- Designing a multi-epitope vaccine againstFrontiers in genetics · 2024Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Multidrug resistance pattern and molecular epidemiology of pathogens among children with diarrhea in Bangladesh, 2019-2021.Scientific reports · 2023Article
- Increasing trend of antibiotic resistance in Shigella in Bangladesh: a plasmid-mediated transfer of mphA macrolide resistance gene.Research square · 2023Article
- Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Antimicrobial resistance against shigellosis is increasingly alarming. However, evidence-based knowledge gaps regarding the changing trends of shigellosis in Bangladesh exist due to the scarcity of longitudinal data on antimicrobial resistance. Our study evaluated the last 20 years antimicrobial resistance patterns against shigellosis among under-5 children in the urban and rural sites of Bangladesh. Data were extracted from the Diarrheal Disease Surveillance System (DDSS) of Dhaka Hospital (urban site) and Matlab Hospital (rural site) of the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) between January 2001 and December 2020. We studied culture-confirmed shigellosis cases from urban Dhaka Hospital (n = 883) and rural Matlab Hospital (n = 1263). Since 2001, a declining percentage of shigellosis in children observed in urban and rural sites. Moreover, higher isolation rates of Shigella were found in the rural site [1263/15684 (8.1%)] compared to the urban site [883/26804 (3.3%)] in the last 20 years. In both areas, S. flexneri was the predominant species. The upward trend of S. sonnei in both the study sites was statistically significant after adjusting for age and sex. WHO-recommended 1st line antibiotic ciprofloxacin resistance gradually reached more than 70% in both the urban and rural site by 2020. In multiple logistic regression after adjusting for age and sex, ciprofloxacin, azithromycin, mecillinam, ceftriaxone, and multidrug resistance (resistance to any two of these four drugs) among under-5 children were found to be increasing significantly (p<0.01) in the last 20 years in both sites. The study results underscore the importance of therapeutic interventions for shigellosis by appropriate drugs based on their current antibiogram for under-5 children. These observations may help policymakers in formulating better case management strategies for shigellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.